Top Canonical Pathway | Â | p-value | Ratio | Genes |
---|---|---|---|---|
miR-132 HVC | ||||
 | Molecular Mechanisms of Cancer | <0.0001 | 0.0301 | E2F5, CFLAR, ADCY3, ARHGEF10, CDKN1A, MAPK1, TGFB2, PRKD1, RAP2B, PRKAG2, FOXO1 |
 | RAR Activation | 0.0001 | 0.0398 | ADCY3, MAPK1, TGFB2, PRKD1, PRKAG2, NCOR1, GTF2H1 |
 | VDR/RXR Activation | 0.0001 | 0.0641 | CDKN1A, TGFB2, PRKD1, NCOR1, FOXO1 |
 | Breast Cancer Regulation by Stathmin1 | 0.0001 | 0.0366 | E2F5, ADCY3, ARHGEF10, CDKN1A, MAPK1, PRKD1, PRKAG2 |
 | ErbB Signaling | 0.0001 | 0.0581 | HBEGF, MAPK1, PRKD1, NRG2, FOXO1 |
 | Pancreatic Adenocarcinoma Signaling | 0.0003 | 0.0472 | E2F5, HBEGF, CDKN1A, MAPK1, TGFB2 |
 | Cell Cycle: G1/S Checkpoint Regulation | 0.0005 | 0.0625 | E2F5, CDKN1A, TGFB2, FOXO1 |
 | PPARα/RXRα Activation | 0.0005 | 0.0335 | ADCY3, MAPK1, TGFB2, CAND1, PRKAG2, NCOR1 |
 | Leptin Signaling | 0.0008 | 0.0541 | ADCY3, MAPK1, PRKAG2, FOXO1 |
 | Acute Myeloid Leukemia Signaling | 0.0009 | 0.0519 | KITLG, MAPK1, TCF7L2, TCF7L1 |
miR-210 Area X | ||||
 | Phospholipase C Signaling | 0.0022 | 0.0126 | ADCY5, BTK, PPP1CB |
 | Dopamine Receptor Signaling | 0.0033 | 0.0256 | ADCY5, PPP1CB |
 | CDK5 Signaling | 0.0052 | 0.0202 | ADCY5, PPP1CB |
 | NAD Biosynthesis III | 0.0066 | 0.1670 | NMNAT2 |
 | Phosphatidylcholine Biosynthesis I | 0.0078 | 0.1430 | PCYT1B |
 | NAD Salvage Pathway III | 0.0078 | 0.1430 | NMNAT2 |
 | Cellular Effects of Sildenafil (Viagra) | 0.0089 | 0.0155 | ADCY5, PPP1CB |
 | β-adrenergic Signaling | 0.0093 | 0.0150 | ADCY5, PPP1CB |
 | Calcium Transport I | 0.0100 | 0.1110 | ATP2B3 |
 | Dopamine-DARPP32 Feedback in cAMP Signaling | 0.0135 | 0.0124 | ADCY5, PPP1CB |